Literature DB >> 16487597

Screening for bipolar disorder in women with polycystic ovary syndrome: a pilot study.

Kimberly G Klipstein1, Joseph F Goldberg.   

Abstract

OBJECTIVE: Previous reports have attributed polycystic ovary syndrome (PCOS) to valproate treatment in women with bipolar disorder and with epilepsy. However, since high rates of mood disorders have been identified in women with PCOS, we sought to investigate the hypothesis that an intrinsic association may exist between PCOS and bipolar disorder, independent of pharmacotherapy.
METHOD: Seventy-eight women identified with PCOS were screened for the presence of bipolar illness using the Mood Disorders Questionnaire (MDQ), a validated self-assessment screen for bipolar disorder.
RESULTS: Twenty-eight percent of subjects had either a previous bipolar diagnosis or met MDQ threshold criteria for bipolar screen positivity. Ninety seven percent of previously diagnosed or MDQ screen-positive subjects had no valproate exposure before PCOS diagnosis. LIMITATIONS: Possible selection bias, lack of direct comparison with a control group, and lack of knowledge of specific diagnostic work up for PCOS, should all be considered in interpretation of these results. The MDQ as a self-report screen may be less sensitive to detect bipolar II or NOS than bipolar I disorder, and was not corroborated by a diagnostic interview.
CONCLUSION: These preliminary findings suggest a higher rate of bipolar screen positivity among women with PCOS than is expected in the general population, independent of an association with valproate. This observed link between PCOS and bipolar screen-positivity is consistent with a possible shared hypothalamic-pituitary-gonadal axis abnormality.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487597     DOI: 10.1016/j.jad.2006.01.011

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  8 in total

1.  A case of successful treatment of comorbid obesity and polycystic ovarian disease with add-on metformin in bipolar disorder.

Authors:  Sri M Agarwal; Rishikesh V Behere; Ganesan Venkatasubramanian; Naren P Rao; Shivarama Varambally; B N Gangadhar
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Predictors of Depression in Iranian Women with Polycystic Ovarian Syndrome.

Authors:  Mojgan Mirghafourvand; Sakineh Mohammad-Alizadeh Charandabi; Tahereh Behroozi Lak; Fatemeh Aliasghari
Journal:  Community Ment Health J       Date:  2017-11-14

Review 3.  Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.

Authors:  Mark O Goodarzi; Daniel A Dumesic; Gregorio Chazenbalk; Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

4.  Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population.

Authors:  Satoshi Kawamura; Chihaya Maesawa; Koji Nakamura; Kazuhiko Nakayama; Michiaki Morita; Yohei Hiruma; Tomoyuki Yoshida; Akio Sakai; Tomoyuki Masuda
Journal:  Neuropsychiatr Dis Treat       Date:  2011-11-01       Impact factor: 2.570

5.  Personality and psychiatric disorders in women affected by polycystic ovary syndrome.

Authors:  Elisabetta Scaruffi; Alessandra Gambineri; Stefania Cattaneo; Jenni Turra; Roberto Vettor; Roberto Mioni
Journal:  Front Endocrinol (Lausanne)       Date:  2014-11-12       Impact factor: 5.555

6.  Sexual dysfunction in patients with polycystic ovary syndrome and its affected domains.

Authors:  Tahereh Eftekhar; Farnaz Sohrabvand; Neda Zabandan; Mamak Shariat; Fedyeh Haghollahi; Akram Ghahghaei-Nezamabadi
Journal:  Iran J Reprod Med       Date:  2014-08

Review 7.  Epidemiology, diagnosis, and management of polycystic ovary syndrome.

Authors:  Susan M Sirmans; Kristen A Pate
Journal:  Clin Epidemiol       Date:  2013-12-18       Impact factor: 4.790

8.  Risk of psychiatric disorders following polycystic ovary syndrome: a nationwide population-based cohort study.

Authors:  Jeng-Hsiu Hung; Li-Yu Hu; Shih-Jen Tsai; Albert C Yang; Min-Wei Huang; Pan-Ming Chen; Shu-Li Wang; Ti Lu; Cheng-Che Shen
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.